Mesoblast Limited: Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
Ryoncil ® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute ...
Too Old to Operate1d
Basophilia at Diagnosis Predicts Worse Outcomes in Several MPNs
Basophilia at diagnosis of myeloproliferative neoplasms was associated with a more aggressive disease phenotype and poorer ...
eLife4d
Identification of a sub-population of synovial mesenchymal stem cells with enhanced treatment efficacy in a rat model of Osteoarthritis
This important study focused on characterizing clonally derived MSC populations from the synovium of normal and osteoarthritis (OA) patients, demonstrating their potential to regenerate cartilage in ...